Abstract
Novel drugs for atherosclerosis have taken a hard hit in the past year, making it unlikely that any will make it to market this decade. But lessons learned from these failures might help the development of successful drugs, experts say.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Opar, A. Where now for new drugs for atherosclerosis?. Nat Rev Drug Discov 6, 334–335 (2007). https://doi.org/10.1038/nrd2326
Issue Date:
DOI: https://doi.org/10.1038/nrd2326
This article is cited by
-
Therapeutic targeting of chemokine interactions in atherosclerosis
Nature Reviews Drug Discovery (2010)
